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Small numbers of proangiogenic bone marrow-derived cells (BMDCs) can play pivotal roles in tumor 
progression. In this issue of Cancer Cell, two papers, utilizing different tumor angiogenesis models, both 
find that activated MMP-9 delivered by BMDCs modulates neovessel remodeling, thereby promoting tumor 
growth. The changes in microvascular anatomy induced by MMP-9-expressing BMDCs are strikingly 
different between the preirradiated tumor vascular bed model employed by Ahn and Brown and the invasive 
glioblastoma model utilized by Du et al., likely mirroring the complexity of the real tumor microenvironment 
and the intricacy of roles of different BMDC populations in mediating tumor neoangiogenesis.The concept that tumor growth mim-
ics reactivation of embryonic develop-
ment is not new. However, only recently 
has it come to light that certain stages 
of tumor blood vessel assembly mimic 
embryonic vasculogenesis. While tumor 
blood vessels may develop by co-
option or sprouting from pre-existing 
vessels (adult angiogenesis), similar to 
that observed in fetal blood vessel for-
mation, circulating vascular progenitor 
cells can also contribute to neovessel 
formation (adult vasculogenesis) (Rafii 
and Lyden, 2008).
Among these modes of tumor vascu-
larization, the contribution of adult vas-
culogenesis has lately been the subject 
of intense scrutiny. Following the obser-
vation that a subset of hematopoietic and 
vascular progenitors could be recruited 
to assemble tumor neovessels (Lyden et 
al., 2001), many studies have examined 
these and other subsets of proangio-
genic BMDCs that are mobilized in can-
cer-bearing animals and in humans. The 
rarity of many of these BMDC subsets 
in tumors has complicated the analysis 
of their respective importance and spe-
cific functions. Nonetheless, several key 
concepts have emerged. First, different 
populations of proangiogenic BMDCs 
have restricted roles in temporally and 
spatially supporting vasculogenesis and 
angiogenesis in specific types of tumors. 
Second, recruitment of even small num-
bers of “catalytic” BMDCs to tumors can 
play a crucial role in tumor progression. Recently, extensive implementation of 
BM transplantation in conjunction with 
various genetic reporter systems and 
immunologic markers has facilitated 
more detailed investigation of these cells 
(Rafii and Lyden, 2008).
There are several categories of BMDCs 
implicated in tumor angiogenesis. One is 
those capable of contributing structur-
ally to neovessels, such as endothelial 
progenitor cells (EPCs) and pericyte 
progenitor cells (PPCs), which incorpo-
rate into the vessel wall, thereby sup-
porting the formation of stable tumor 
vessels. Other subsets of BMDCs are 
distinct populations of myeloid progeni-
tors, including Gr1+CD11b+ (Yang et al., 
2004) and dendritic precursors (Conejo-
Garcia et al., 2004) that can differentiate 
into endothelial-like cells and incorpo-
rate lumenally into the tumor neovessels 
through a poorly characterized process. 
Yet another important class of BMDCs 
contributes indirectly to neovasculariza-
tion by incorporating perivascularly or 
by delivering cytokines and other key 
signals that enhance angiogenesis. This 
includes CXCR4+VEGFR1+ hemangio-
cytes (Jin et al., 2006), immune accessory 
cells, and tumor-associated monocytes/
macrophages (TAMs) and inflammatory 
neutrophils (Ardi et al., 2007; Shojaei et 
al., 2007; Condeelis and Pollard, 2006; 
Grunewald et al., 2006).
How do BMDCs home to neovascular-
ization sites? One paradigm is provided 
by the case of CXCR4+VEGFR1+ heman-Cancer Cgiocytes (Jin et al., 2006). Under hypoxic 
conditions, upregulated VEGF-A and 
SDF-1 (CXCL12), through interaction with 
their cognate receptors, VEGFR1 and 
CXCR4, induce the release of activated 
matrix metalloproteinase-9 (MMP-9) 
within the BM. Activated MMP-9 liber-
ates soluble kit-ligand, thereby mobiliz-
ing CXCR4+ BMDC from the BM into the 
circulation (Heissig et al., 2002). These 
cells then home to and are retained 
within peripheral sites of SDF-1 produc-
tion, such as the tumor vascular bed 
(Figure 1).
Among the proangiogenic factors 
that BMDCs manufacture or by which 
BMDCs themselves are regulated, 
MMP-9 has emerged as a major player. 
As an enzyme capable of cleaving many 
structural extracellular matrix compo-
nents and other secreted proteins, the 
proangiogenic functions of MMP-9 are 
myriad, ranging from directly facilitat-
ing endothelial cell invasion to liberat-
ing bioactive growth factors (Seandel 
et al., 2001). Tumor cells, stromal cells 
(e.g., fibroblasts), and BMDCs serve as 
the primary sources of MMP-9 that may 
directly affect distant angiogenic sites 
and bone marrow (Heissig et al., 2002). 
However, the clinical significance of 
MMP-9 delivered by BMDCs locally to the 
tumor was not previously appreciated. 
Two new studies in this issue address 
the underlying problem of why conven-
tional antitumor therapies may ultimately 
fail, and both point to the role of MMP-9-ell 13, March 2008 ©2008 Elsevier Inc. 181
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PreviewsFigure 1. Multifaceted Role of MMP-9 in Supporting Mobilization and Recruitment of Bone Marrow-Derived Cells in Tumor Vasculogenesis 
and Neoangiogenesis
Activated MMP-9, through increasing the bioavailability of Kit-ligand, VEGF-A, and SDF-1, supports the mobilization of the proangiogenic bone marrow-derived 
cells (BMDCs), including tumor-associated monocytes/macrophages (TAMs), Gr1+CD11b+ myeloid precursors, CXCR4+VEGFR1+ hemangiocytes, and EPCs 
to the circulation. Irradiation-induced vascular injury or hypoxia-driven upregulation of HIF-1α enhances the release of SDF-1 and VEGF-A, thereby recruiting 
MMP-9-bearing BMDCs to the neoangiogenic niches, augmenting tumor vasculogenesis, angiogenesis, invasive potential, and metastasis. MMP-9 delivered by 
BMDCs amplifies tumor neoangiogenesis by increasing the bioavailability of VEGF-A and stem cell active chemocytokines, including SDF-1 and Kit-ligand.expressing BMDCs in modulating micro-
vascular anatomy. Remarkably, the spe-
cific type of vascular remodeling driven 
by BMDC-derived MMP-9 appears to be 
highly dependent on the type of tumor 
and its defined microenvironment.
Ahn and Brown investigate an impor-
tant clinical issue of tumor recurrence 
in the irradiated area after radiother-
apy using a model in which the tumor 
vascular bed has been damaged by 
irradiation (Ahn and Brown, 2008). 
Based on previous work, preirradia-
tion has the effect of largely abolishing 
sprouting angiogenesis and retarding 
tumor growth. The authors found that 
CD11b+ cells represent the predomi-
nant component of BMDCs in mam-
mary MT1A2 carcinomas. Not only 
did CD11b+ BMDCs increase in preir-
radiated MT1A2 tumors, but levels of 
MMP-9 were also higher, compared 
to nonpreirradiated control tumors. 
Correspondingly, when tumors were 182 Cancer Cell 13, March 2008 ©2008 Elsegrown in MMP-9 knockout (KO) mice, 
those in preirradiated beds were much 
smaller and had decreased vessel den-
sity compared to those in WT control 
beds. Using transplantation assays, 
the authors found that the presence of 
MMP-9 either in the host stroma or in 
the hematopoietic compartment was 
sufficient to restore vessel density to 
control levels. Notably, the tumor ves-
sels in the preirradiated bed tended 
to be low in pericyte coverage com-
pared to nonirradiated controls in WT 
mice, attributed to robust production 
of immature vessels. In contrast, con-
comitant blockade of angiogenesis (via 
preirradiation) and of vasculogenesis 
(in the absence of MMP-9) resulted in 
small tumors containing only mature-
appearing sparse vessels, likely repre-
senting co-opted preexisting host vas-
culature, as a “default” mode of tumor 
vascularization. Thus, the impaired angio-
genesis of the preirradiated tumor bed vier Inc.unmasked the ability of MMP-9+ BMDCs 
to restore neovascularization.
In contrast, Du et al. follow up their 
previous observation that orthotopic 
HIF-1α KO glioblastoma multiforme 
(GBM) tumors exhibit relatively dense 
organized microvessels, compatible with 
co-option of host vasculature, compared 
to WT GBM that undergo extensive vas-
cular remodeling. In the current study, 
the authors use an array of GBM implan-
tation and bone marrow transplantation 
models to show that HIF-1α-dependent 
recruitment of proangiogenic MMP-9-
bearing BMDCs results in more tumor 
neovascularization (Du et al., 2008). 
In the absence of MMP-9, there is less 
vascular remodeling, and the vascula-
ture resembles that of the normal brain. 
Their data suggest that MMP-9 liberates 
matrix-bound VEGF-A, resulting in more 
VEGF-A/VEGFR2 complex formation, 
pericyte activation, and vascular remod-
eling. The authors also show that MMP-9 
Cancer Cell
Previewsfacilitates the recruitment of EPCs and 
PPC. In the absence of MMP-9 there is 
relatively less pericyte investment, and 
this results in diminished tumor neovas-
cularization.
Although the authors show that PPC 
and EPC recruitment is MMP-9 depen-
dent, they also show that tumor infil-
tration of the majority of the BMDC is 
dependent upon SDF-1 expression lev-
els. Inhibiting the recruitment of BMDC 
by treating mice carrying WT-GBM with 
a CXCR4 antagonist, the authors were 
able to normalize the vascular architec-
ture and block tumor neovasculariza-
tion.
A key but unexpected finding in this 
manuscript is the paradoxical ability of 
VEGF-A to directly regulate GBM inva-
sion. GBM normally invades adjacent 
parts of the brain by single cells infil-
trating into the brain parenchyma. In 
the absence of VEGF-A or MMP-9, this 
mode of invasion is blocked and leads to 
a yet unrecognized mechanism causing 
deep invasion of the GBM, by using the 
co-opted blood vessels as a roadmap, 
in a mode known as perivascular tumor 
invasion. The data reveal the poten-
tial of GBM to adapt to its changing 
microenvironment and underscore the 
importance of multimodality and mul-
titargeted treatment of tumors, aimed 
not only at the microenvironment and 
the tumor but also on different proan-
giogenic BMDCs that promote tumor 
progression.
The alternative modes of GBM inva-
sion have pivotal clinical implications. 
Many of the newest treatment regimens 
under clinical investigation for patients 
with GBM result in either blocking 
VEGF-A/VEGFR2 interaction or possi-
bly increasing the amount of BM cells 
circulating in the blood. If these findings are confirmed in humans, then such 
treatments may inflict unrecognized 
damage.
Collectively, the data from the two 
studies suggest that there is significant 
variation in utilization of BMDCs and 
bioavailability of MMP-9 between dif-
ferent tumor models. One might expect 
even greater natural variation in utili-
zation of BM-derived cells and their 
MMP-9 between human tumor types or 
perhaps even within a given tumor clas-
sification. At an extreme, it is possible 
that the observed clinical variation in 
behavior between different metastatic 
foci within individual patients could be 
due to local differences in recruitment 
of BM-derived cells. However, both 
studies find that a minimum threshold 
of MMP-9 is required for robust angio-
genesis, but the source of the MMP-9 
may be less critical than its presence. 
With the additional layers of complexity 
revealed in the current studies, it is per-
haps not surprising that broad-spec-
trum MMP inhibitors failed to produce 
dramatic responses in clinical trials or 
that antiangiogenic therapy as currently 
implemented has limited efficacy. In this 
vein, it should be noted that MMP-9 
might have antiangiogenic properties as 
well, through liberation of matrix-bound 
inhibitors such as tumstatin (Hamano et 
al., 2003). Until these subtle features of 
tumor biology are fully interrogated and 
placed in context, we must proceed with 
caution, mindful of both intended and 
potential unintended consequences of 
treatment.
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